Rocket shares surge 14.29% in premarket after FDA fast-tracks Kresladimarnetegragene autotemcel, the first gene therapy for severe LAD-I.

Rocket surged 14.29% in premarket trading, following the FDA's accelerated approval of Kresladimarnetegragene autotemcel, making it the first gene therapy globally for severe LAD-I. Rocket is a late-stage biotech company focused on gene therapies for rare genetic diseases, with multiple platform pipelines in cardiology and hematology, as well as self-built cGMP manufacturing capacity and end-to-end commercialization capabilities.